Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism

Nuclear Medicine Communications

Volumn 30, Issue 2, 2009, Pages 160-168

  Chen, Dan Yun ^a   Jing, Jin ^b   Schneider, Peter F ^c,d   Chen, Tang Hua ^a  

^a First Affiliated Hospital   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Autoimmunity; Hyperthyroidism; Radioiodine treatment; Thyroid diseases; Thyroid nodules

Indexed keywords

ANTITHYROID AGENT; IODINE 131; PROPRANOLOL DERIVATIVE; PROPYLTHIOURACIL; THIAMAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; EUTHYROIDISM; EYE DISEASE; FEMALE; GOITER; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITHYROID AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; LONGITUDINAL STUDIES; MALE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 58649103517     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283134d4d     Document Type: Article

References (40)

1. Yao B. Thyroid disease study: basic and clinical [in Chinese]. Beijing: Scientific and Technical Documents Publishing House; 2003.
2. Zen XX, Yuan Y, Liu Y, Wu TX, Han S. Chinese herbal medicines for hyperthyroidism. Cochrane Database Syst Rev 2007; 18:CD005450.
3. Gang ZC. Radionuclide therapy of thyroid diseases [in Chinese]. Beijing: Atomic Energy Press; 2003.
4. Bolanos F, Gonzá;lez-Ortiz M, Duróon H, Sánchez C. Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin 2002; 54:307-310.
5. Gao Y, Zhao MH, Ye H, Guo XH. Clinical characteristics of nineteen vasculitis patients associated with propylthiouracil-induced antineutrophil cytoplasmic antibody. Zhonghua Nei Fen Mi Dai Xie Za Zhi 2006; 22: 124-126.
6. Gao Y, Zhao MH, Guo XH, Xin G, Gao Y, Wang HY. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 2004; 30:205-213.
7. 131Iodine treatment of thyroid diseases [in Chinese]. Beijing: People's Medical Publishing House; 2002. pp. 265-267.
8. Iagaru A, McDougall R. Treatment of thyroid toxicosis [in Chinese]. J Nucl Med 2007; 48:379-389.
9. Burch HB, Wartofsky L Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747-793.
10. 131I and antithyroid drugs in the treatment of Graves' disease in children. Zhonghua Er Ke Za Zhi 2005; 43:507-509.
11. 131I treatment. Zhonghua He YiXue Za Zhi 2006; 26:304-305.
12. 131I efficacy for 110 hyperthyroidism patients under 20 years old. Zhonghua Nei Fen Mi Dai Xie Za Zhi 2002; 18:307-308.
13. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338:73-78.
14. Perros P, Kendall-Taylor P Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrtnol Metab 2005; 90:5321-5323.
15. 131I with pretreatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun 2004; 25:675-682.
16. Calegaro JU, De Freitas Gomes E, Bae SH, Ulyssea R, Casulari LA. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration. Panminerva Med 2000; 42:241-245.
17. Aitken M, George A, Bodmer C, Cameron J. The efficacy of low-dose radioactive iodine without a thionamide in the treatment of thyrotoxicosis. Clin Med 2003; 3:265-267.
18. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, Balon HR. Procedure guideline for therapy of thyroid disease with iodine-131. J Nucl Med 2002; 43:856-861.
19. Dietlein M, Dressier J, Grunwald F, Leisner B, Moser E, Reiners CHR, et al. Guideline for radioiodine therapy for benign thyroid diseases (version 3). Nucl Med 2004; 43:217-220.
20. 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med 1999; 55:215-221.
21. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991; 34:71-76.
22. Premawardhana LDKE, Parkes AB, John R, Harris B, Lazarus JH. Thyroid peroxidase antibodies in early pregnancy (utility for prediction of postpartum thyroid dysfunction and implications for screening). Thyroid 2004; 14:610-615.
23. Kita T, Yokoyama K, Kinuya S, Taki J, Michigishi T, Tonami N. Single dose planning for radioiodine-131 therapy of Graves' disease. Ann Nucl Med 2004; 18:151-155.
24. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 2002; 12:135-139.
25. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM. Radioiodide therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002; 29:1118-1124.
26. Rivkees S. Radioactive iodine use in childhood Graves' disease: time to wake up and smell the 1-131. J Clin Endocrinol Metab 2004; 89:4227-4228.
27. Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goiter? Eur J Nucl Med 2001; 28:1360-1364.
28. Schneider P, Biko J, Hänscheid H, Hilliger S, Koutsampelas C, Kranzfelder M, et al. The route of administration (oral vs. intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy. Eur J Nucl Med 2003; 2:788-793.
29. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicenter study. Eur J Clin Invest 1995; 25:186-193.
30. Stinzing A, Schneider P, Reiners C. Documentation of therapy results and outcome after radioiodine therapy (RIT) in benign thyroid disease using a database application [in German]. Nuklearmedizin 2005; 44:A111.
31. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61:641-648.
32. Radioiodine in the management of benign thyroid disease: Clinical guidelines. Report of a working party 2007. The Lavenham Press Ltd., Sudbury Suffolk. ISBN 978-1-86016-297-8.
33. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE; Basedow Study Group. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005; 15:1047-1054.
34. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228-238.
35. Albino CC, Mesa CO Jr, Olandoski M, Ueda CE, Woellner LC, Goedert CA. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radloiodine. J Clin Endocrinol Metab 2005; 90:2775-2780.
36. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf) 2004; 61:232-238.
37. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294:71-80.
38. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M. Risk of ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89:3365-3370.
39. De Luis DA, Arconada A, Aller R, Cuéllar LA, Terroba MC, Matin Gil J. Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole. Med Clin (Bare) 2002; 118:777-778.
40. Menendez Torre E, Anda Apinaniz E, Barberia Layana JJ. Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease. Multicenter study in Northern Spain. Rev Clin Esp 2000; 200:69-73.